Mark C. Scholz

5.9k total citations
36 papers, 740 citations indexed

About

Mark C. Scholz is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark C. Scholz has authored 36 papers receiving a total of 740 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark C. Scholz's work include Prostate Cancer Treatment and Research (29 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Prostate Cancer Diagnosis and Treatment (13 papers). Mark C. Scholz is often cited by papers focused on Prostate Cancer Treatment and Research (29 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Prostate Cancer Diagnosis and Treatment (13 papers). Mark C. Scholz collaborates with scholars based in United States, United Kingdom and Canada. Mark C. Scholz's co-authors include Stephen B. Strum, Henry J. Johnson, Richard Y. Lam, Glenn Tisman, J E McDermed, Robert I. Jennrich, E. David Crawford, Rajesh Kaldate, Michael K. Brawer and Abebe Haregewoin and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Urology.

In The Last Decade

Mark C. Scholz

34 papers receiving 713 citations

Peers

Mark C. Scholz
Seiji Arai Japan
Bruce Keith United States
Felipe Melo Cruz Brazil
Sagar Sardesai United States
Thomas Spires United States
Charles S. Dai United States
Syed A. Ahmed United States
Atsushi Hayata Japan
Ramiro Castro‐Santamaria United States
Rikiya Taoka Japan
Seiji Arai Japan
Mark C. Scholz
Citations per year, relative to Mark C. Scholz Mark C. Scholz (= 1×) peers Seiji Arai

Countries citing papers authored by Mark C. Scholz

Since Specialization
Citations

This map shows the geographic impact of Mark C. Scholz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark C. Scholz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark C. Scholz more than expected).

Fields of papers citing papers by Mark C. Scholz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark C. Scholz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark C. Scholz. The network helps show where Mark C. Scholz may publish in the future.

Co-authorship network of co-authors of Mark C. Scholz

This figure shows the co-authorship network connecting the top 25 collaborators of Mark C. Scholz. A scholar is included among the top collaborators of Mark C. Scholz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark C. Scholz. Mark C. Scholz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weidhaas, Joanne B., Nicholas De Marco, Anusha Kalbasi, et al.. (2022). Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. Journal for ImmunoTherapy of Cancer. 10(2). e003625–e003625. 17 indexed citations
2.
Dorff, Tanya B., Yosuke Hirasawa, Jared D. Acoba, et al.. (2021). Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. Journal for ImmunoTherapy of Cancer. 9(8). e002931–e002931. 28 indexed citations
3.
Dorff, Tanya B., Jared D. Acoba, Sumanta K. Pal, et al.. (2020). Assessing different sequencing regimens of atezolizumab (atezo) and sipuleucel-T (sipT) in patients who have asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology. 38(6_suppl). 141–141. 3 indexed citations
4.
Rosser, Charles J., Yosuke Hirasawa, Jared D. Acoba, et al.. (2020). Phase Ib study assessing different sequencing regimens of atezolizumab (anti-PD-L1) and sipuleucel-T (SipT)in patients who have asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.. Journal of Clinical Oncology. 38(15_suppl). e17564–e17564. 11 indexed citations
5.
Scholz, Mark C., et al.. (2019). Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate Cancer. Clinical Genitourinary Cancer. 18(4). e397–e401. 9 indexed citations
6.
Weidhaas, Joanne B., et al.. (2018). Pembrolizumab for recurrent or advanced prostate cancer.. Journal of Clinical Oncology. 36(6_suppl). 250–250. 5 indexed citations
7.
Scholz, Mark C., et al.. (2017). Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer. ImmunoTargets and Therapy. Volume 6. 11–16. 49 indexed citations
8.
Scholz, Mark C.. (2015). Sipuleucel-T in combination with mini-dose ipilimumab for metastatic, castrate-resistant prostate cancer.. Journal of Clinical Oncology. 33(15_suppl). e22104–e22104. 2 indexed citations
9.
10.
11.
Scholz, Mark C., et al.. (2011). Primary Intermittent Androgen Deprivation As Initial Therapy for Men with Newly Diagnosed Prostate Cancer. Clinical Genitourinary Cancer. 9(2). 89–94. 8 indexed citations
12.
13.
Scholz, Mark C., et al.. (2006). Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period. The Journal of Urology. 175(5). 1673–1678. 24 indexed citations
14.
Scholz, Mark C., et al.. (2006). Ultrasensitive PSA nadir on testosterone inactivating pharmaceuticals accurately predicts early prostate cancer progression. Journal of Clinical Oncology. 24(18_suppl). 14531–14531. 1 indexed citations
15.
16.
Scholz, Mark C., et al.. (2003). Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer and Prostatic Diseases. 6(4). 301–304. 72 indexed citations
17.
Jennrich, Robert I., et al.. (2002). Using splines to detect changes in PSA doubling times. The Prostate. 54(2). 88–94. 11 indexed citations
18.
Strum, Stephen B., et al.. (2000). Intermittent Androgen Deprivation in Prostate Cancer Patients: Factors Predictive of Prolonged Time Off Therapy. The Oncologist. 5(1). 45–52. 52 indexed citations
19.
Scholz, Mark C. & Stephen B. Strum. (1999). RE: RECOVERY OF SPONTANEOUS ERECTILE FUNCTION AFTER NERVE-SPARING RADICAL RETROPUBIC PROSTATECTOMY WITH AND WITHOUT EARLY INTRACAVERNOUS INJECTIONS OF ALPROSTADIL. The Journal of Urology. 161(6). 1914–1915. 7 indexed citations
20.
Strum, Stephen B., J E McDermed, Mark C. Scholz, Henry J. Johnson, & Glenn Tisman. (1997). Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. British Journal of Urology. 79(6). 933–941. 159 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seiji Arai Breakdown of academic impact, for papers by Bruce Keith Breakdown of academic impact, for papers by Felipe Melo Cruz Breakdown of academic impact, for papers by Sagar Sardesai Breakdown of academic impact, for papers by Thomas Spires Breakdown of academic impact, for papers by Charles S. Dai Breakdown of academic impact, for papers by Syed A. Ahmed Breakdown of academic impact, for papers by Atsushi Hayata Breakdown of academic impact, for papers by Ramiro Castro‐Santamaria Breakdown of academic impact, for papers by Rikiya Taoka
Rankless by CCL
2026